Ftse Mib
33.778,57
0,09%
DAX
17.914,99
-0,04%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
57.686,45
-0,95%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aligos Therapeutics Inc (ALGS) Aligos Therapeutics Inc (ALGS) Notizie

Aligos Therapeutics Inc

ALGS
0,77
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202422:05GLOBEAligos Therapeutics to Announce 1st Quarter 2024 Financial..
25/4/202422:05GLOBEAligos Therapeutics Presents Positive Clinical Data at..
25/4/202414:00GLOBEAligos Therapeutics Mourns the Passing of MASH Industry..
09/4/202414:00GLOBEAligos Therapeutics to Participate in the Piper Sandler..
03/4/202414:00GLOBEAligos Therapeutics Announces First Subjects Dosed in the..
27/3/202413:00GLOBEAligos Therapeutics Presents Positive Clinical Data at APASL..
18/3/202413:00GLOBEAligos Therapeutics Announces the Initiation of the Phase 2a..
12/3/202421:05GLOBEAligos Therapeutics Reports Recent Business Progress..
05/3/202422:05GLOBEAligos Therapeutics to Announce 4th Quarter 2023 Financial..
04/3/202423:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202423:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202423:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202414:00GLOBEAligos Therapeutics To Participate in the Leerink Partners..
20/2/202414:00GLOBEAligos Therapeutics to Host KOL Event to Discuss Phase 2a..
13/2/202414:00GLOBEAligos Therapeutics Strengthens Finance Leadership Team with..
30/1/202413:04EDGAR2Form SC TO-I - Tender offer statement by Issuer
25/1/202412:12EDGAR2Form SC TO-C - Written communication relating to an issuer..
25/1/202412:06EDGAR2Form 8-K - Current report
28/11/202322:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/11/202322:05EDGAR2Form 8-K - Current report
17/11/202322:38EDGAR2Form S-3 - Registration statement under Securities Act of..
15/11/202322:01EDGAR2Form 8-K - Current report
07/11/202318:03EDGAR2Form D - Notice of Exempt Offering of Securities
02/11/202321:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:08EDGAR2Form SC 13G - Statement of acquisition of beneficial..
02/11/202321:05EDGAR2Form 8-K - Current report
25/10/202323:05EDGAR2Form 8-K - Current report
18/10/202314:45EDGAR2Form 8-K - Current report
12/9/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202322:01EDGAR2Form 8-K - Current report
03/8/202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:05EDGAR2Form 8-K - Current report
01/8/202322:52EDGAR2Form 8-K - Current report
25/7/202322:02EDGAR2Form 8-K - Current report
21/7/202322:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: Min: Max:
Chiusura: 0,77

La tua Cronologia

NASDAQ
ALGS
Aligos Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network